EP Patent

EP1191026B1 — New pyridazine endothelin antagonists

Assigned to Pfizer Ltd Great Britain · Expires 2004-05-19 · 22y expired

What this patent protects

Compounds of formula (I) have affinity for endothelin receptors, are selective for ETA over ETB, and are potentially useful in the treatment of conditions mediated by endothelin. <CHEM>

USPTO Abstract

Compounds of formula (I) have affinity for endothelin receptors, are selective for ETA over ETB, and are potentially useful in the treatment of conditions mediated by endothelin. <CHEM>

Drugs covered by this patent

Patent Metadata

Patent number: EP1191026B1
Jurisdiction: EP
Classification: —
Expires: 2004-05-19
Drug substance claim: No
Drug product claim: No
Assignee: Pfizer Ltd Great Britain
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.